1

A hybrid computer vision model to predict lung cancer

in diverse populations

Abdul J. Zakkar MD[1,2], Nazia Perwaiz PhD[3], Weiheng Zhong BS[4], Alex Krule MD[1],

Mason Burrage-Burton BS[1], Vijeth Narra MS[1], Farah Yousef BS[1,2], Daniel Kim BS[1],

Vijayakrishna K. Gadi MD PhD[1], Mark C. Korpics MD[5], Sage J. Kim PhD[6],

Aly A. Khan PhD[7], Yamilé Molina PhD[6], Yang Dai PhD[8], G. Elisabeta Marai PhD[9],

Hadi Meidani PhD[4], Ryan H. Nguyen DO[1], Ameen A. Salahudeen MD PhD[1,2,10*]

Departments of [1]Medicine, [2]Biochemistry & Molecular Genetics, [5]Radiation Oncology,
[8]Bioengineering, College of Medicine, University of Illinois at Chicago

[3]School of Electrical Engineering and Computer Science, National University of Science and
Technology, Islamabad, Pakistan.

[4]Department of Civil & Environmental Engineering, Grainger College of Engineering, University
of Illinois Urbana Champaign

[6]School of Public Health, University of Illinois at Chicago

[7]Department of Pathology, Biological Sciences Division, University of Chicago

[9]Department of Computer Science, College of Engineering, University of Illinois at Chicago

[10]AI.Health4All Center for Health Equity using Machine Learning and Artificial Intelligence,
University of Illinois at Chicago

*Correspondence: 840 S. Wood St., 820E CSB, Chicago, IL 60612; ameen@uic.edu

Word Count: Abstract = 394, Manuscript = 3,854

KEY POINTS

Question Can artificial intelligence (AI) tools for cancer detection using clinical information and

screening low dose lung CT equitably estimate the development of lung cancer in diverse

populations to overcome racial disparities in lung cancer screening?

Findings In this study of 53,452 participants from the National Lung Screening Trial and

11,654 participants in University of Illinois Health cohorts, a Hybrid computer vision model

predicted development of lung cancer with high accuracy based on Receiver Operating

Characteristic (ROC) AUC performance of 0.78-0.91 years 1-6 after low dose CT. A disparity in

performance was observed in Black, but not White participants, in the UIH cohort with ROC-

AUC ranging from 0.63-0.72. Retraining the computer vision component of the model with a

greater number of Black subjects improved ROC-AUC performance to 0.70-0.87.

Meaning This study suggests that AI tools can be optimized to equitably estimate future lung

cancer risk to identify high risk individuals who may benefit from preventive measures, including

supplemental screening.

ABSTRACT

Importance – Disparities of lung cancer incidence exist in Black populations which have the highest rates of lung cancer in the US. Current age and tobacco-based screening criteria underserve Black populations due to disparately elevated rates of lung cancer in the screening eligible population. Individualized risk-based screening is a potential means to mitigate these disparities.

Objective – To evaluate prediction models that integrate clinical and imaging-based features to individualize lung cancer risk as an alternative to existing screening criteria associated with disparities.

Design – This cross-sectional study utilized participants from the National Lung Screening Trial (NLST) and a population-based cohort of University of Illinois Health system (UIH) of individuals at risk of lung cancer with available lung CT imaging and follow up between the years 2015 and 2024.

Setting – Multicenter (NLST) and population based (UIH, urban and suburban Cook County)

Participants – 53,452 in NLST and 11,654 in UIH were included based on age and tobacco use based risk factors for lung cancer. Cohorts were used for both training and testing of deep and machine learning models using clinical features alone or in combination with CT image features (hybrid computer vision).

Exposure – Continuous model risk predictions for multiple years after CT imaging ranging from 0 to 100 with increasing values indicating a higher likelihood of lung cancer.

Main Outcomes and Measures – Accuracy of models based on receiver operating characteristic

curve area under the curve (ROC-AUC) across different racial and other demographic groups.

Results – An optimized 7 clinical feature model achieved ROC-AUC values ranging 0.64-0.67 in

NLST and 0.60-0.65 in UIH cohorts across multiple years. Incorporation of imaging features to

form a hybrid computer vision model significantly improved ROC-AUC values to 0.78-0.91 in

NLST but deteriorated in UIH with ROC-AUC values of 0.68-0.80, attributable to Black

participants where ROC-AUC values ranged from 0.63-0.72 across multiple years. Retraining

the hybrid-Computer Vision model by incorporating Black and other participants from the UIH

cohort improved performance with ROC-AUC values of 0.70-0.87 in a held out UIH test set.

Conclusions and Relevance – Hybrid computer vision demonstrated individualized lung cancer

risk predictions with improved accuracy compared to clinical risk models alone. However,

potential biases in image training data reduced model generalizability in Black participants.

Performance was improved upon retraining with a subset of the UIH cohort, suggesting that

inclusive training and validation datasets can minimize racial disparities thereby improving

health equity upon clinical use.

INTRODUCTION

Lung cancer treatment in the United States carries health disparities in minority populations and are especially pronounced in Black individuals[1]. Low-dose CT (LDCT) lung cancer screening shifts diagnosis to early-stage disease and is associated with reduced mortality[2,3], but stringent eligibility criteria from the United States Preventive Services Task Force (USPSTF)[4] exacerbates disparities in Black populations[4-6]. These criteria, specifically regarding age and duration of tobacco usage, were derived from risk/benefit analysis of the ~ 92% White National Lung Screening Trial (NLST) cohort. This results in exclusion of at-risk Black patients from screening. The eligibility to incidence ratio measures this disparity, and according to current USPSTF guidelines, White populations often have >100 eligible patients screened for one incidence of lung cancer, whereas in Black populations this is reduced to approximately 50 eligible patients for every diagnosed case of lung cancer[4].

Our institution[7] and others[6,8,9] have identified that individualized selection using clinical feature-based risk models improved lung cancer screening eligibility and sensitivity in minoritized populations as compared to USPSTF guidelines. Moreover, individualized lung cancer risk prediction from LDCT images has been achieved using Convolutional Neural Networks (CNNs)[10-13]. Taken together, risk prediction models have the potential to guide screening selection and eligibility, aide the ordering physician and radiologist in determining follow up imaging interval and mitigate lung cancer disparities in early detection and survival. However, these models have been trained and evaluated on cohorts which underrepresent minorities. To advance these risk models for implementation, their generalizability requires assessments in minority populations including Black patients who have the highest annual lung cancer incidence in the United States[14].

In this study, we developed a hybrid computer vision model that integrates clinical and imaging

features to predict individual lung cancer risk. We evaluated the hybrid computer vision model's

predictions in both the National Lung Screening Trial (NLST) cohort and assembled a diverse

urban and suburban real-world patient population across multiple sites in Cook County within

the Chicago metropolitan area (University of Illinois Health, UIH) altogether representing 65,106

participants including 8,823 self identified as Black. Model risk predictions were evaluated

against ground-truth lung cancer diagnoses to determine whether performance was accurate

and equitable across various subpopulations.

METHODS

Research analysis was carried out under approved UIC IRB protocols 2023-1321 and 2023-

1377. The NLST is a multicenter cohort and has been previously described[2]. Cook county is

racially, socioeconomically, and geographically diverse and has regions with higher rates of lung

cancer, predominantly in areas populated by Black patients[15-17]. We assembled a real-world

cohort of 11,654 participants treated in urban and suburban settings in the city of Chicago as

well as greater Cook County. This population based cohort, including 6,447 Black patients with

history of smoking and/or lung cancer, was filtered based on available lung/chest CT studies.

Collecting Data: NLST

Deidentified NLST data was accessed from the National Cancer Institute Cancer Data Access

System approved under approved UIC IRB Protocol 2023-1321.

Collecting Data: UIH Lung Cancer Screening

To assess the hybrid model in the UIH population, we assembled a retrospective cohort of

patients with a history of smoking under approved UIC IRB protocol 2023-1377. Inclusion

criteria for this cohort is listed in **eTable 1**. Briefly, participants were placed into the cohort to

mimic USPSTF lung cancer screening eligibility criteria with ages 50-80 and a history of tobacco

use, and/or based on ICD codes for smoking cessation counseling and cigarette smoking, and

through documented history of smoking. ICD-9 code 305.1 and ICD-10 code F17 were used to

include LDCT procedures to capture participants who may have had missing data in tobacco

data tables from the EHR. LDCT associated DICOMS were chosen through a filtering schema

(**eFigure 1**). A diagnosis of lung cancer was determined based on ICD codes of neoplasm of

bronchus or lung (ICD-9 162, ICD-10 C34), since 10-15 percent of patients at UIH receive

stereotactic body radiation therapy without biopsy proven lung cancer. Deidentified data from

positive cases were verified by A.A.S., a board-certified medical oncologist with sub

specialization in thoracic oncology. Those without a diagnosis of lung cancer and engagement

in the EHR during the retrospective window were assumed to have no lung cancer at the time of

the preparation of this manuscript. Median duration of follow-up between LDCT scans was 431

days and the median number of LDCT scans per participant with at least one LDCT was 1 (the

median is 5 if each convolution kernel and reconstruction of a given LDCT exam is counted

separately).

<u>Generating Ground Truth</u>

The ground truth is represented by six values (1 or 0) indicating the presence or absence of a

lung cancer diagnosis 1 to 6 years after a CT scan was performed. Using the Python

programming language, a data frame was created which represents the ground truth associated

with each LDCT in both the NLST and UIH data sets. The time of each CT event was compared

to the time of the lung cancer diagnosis event of the associated participant. If the difference is

less than or equal to a given number of years, it is labeled as a positive sample (1), otherwise it

is labeled as a negative sample (0). However, if the sample has no known lung cancer

diagnosis event, and the number of years exceeds the number of days to last follow-up event

(or in the case of UIH data, the date 3/16/2024), then the sample is excluded in that specific

follow up period due to a lack of information in determining the ground truth. Over years 1-6,

1888, 3128, 3828, 4056, 4476, and 4884 studies were removed from the UIH cohort

respectively (i.e. 5,980 LDCT studies initially, then 4092 with one year of follow up, etc.). The

NLST data set includes the number of days to the last known cancer status of each participant,

and this was used in a similar manner to remove 4, 35, 159, 280, 461, and 1082 samples (out of

11,980) from the NLST data test set for each respective year.

<u>Training and Test set selection in NLST</u>

A training set from the NLST was created using the same split as previously described[10] with

each sample representing an individual. In addition, data from participants in the chest X-ray

arm of NLST were also incorporated. The SVM models which incorporate imaging features via

ResNet scores were also trained using the same training set, however each sample represents

a single CT scan rather than an individual.

<u>Test set selection in UIH</u>

Data from the UIH cohort consisted of various Digital Imaging and Communications in Medicine

(DICOM) types, a digital format for storing CT scans and associated metadata. LDCTs were

selected using a schema detailed in **eFigure 1**.

<u>Prediction with $PLCO_{m2012}$</u>

$PLCO_{m2012}$ is a logistic regression model for lung cancer risk inference and was evaluated on

NLST data. The $PLCO_{m2012}$ model was published in 2012, and was created using a set of 11

chosen features to predict the probability of lung cancer diagnosis for a given participant within

6 years: age, race, education, Body-Mass Index (BMI), presence of Chronic Obstructive

Pulmonary Disease (COPD), personal history of cancer, family history of lung cancer, smoking

status, cigarettes per day, duration of smoking, and duration of quitting. All 11 features are

directly represented or can be extracted from the data in the NLST. The PLCO$_{m2012}$ logistic

regression model is represented in an R package created by the authors of PLCO$_{m2012}$[16]. This

was translated to Python code to facilitate incorporation with the remainder of the code base.

When using PLCO$_{m2012}$ for prediction, each sample represents an individual participant. The

model was used to generate predictions for probability of lung cancer diagnosis within 6 years

only (it was not used to evaluate performance within 1 to 5 years) as intended by its authors[18].

<u>SVM Prediction</u>

Clinical data elements from the NLST were evaluated for inclusion in a SVM using the Scikit-

Learn Python library[19]. 11 features were retained after recursive feature elimination using linear

kernel. We started with a large set of initial features from those available in NLST, as well as

some generated features which were calculated from existing ones, such as BMI. Recursive

feature elimination showed best results when using 11-13 features. Six unique SVMs were then

trained to make predictions 1-6 years post CT scan, with each sample being an individual

participant. Each of the 6 SVM models was then evaluated on the test sets using the

corresponding ground truths. Additional SVM models were created using a truncated set of

features for more practical utility using highly populated EHR fields, and to also allow for

comparison between UIH and NLST cohorts where features had a high preponderance data

missingness. The training and prediction pipeline of SVM method is depicted in **eFigure 2**.

<u>ResNet Prediction</u>

DICOM data files were evaluated by a ResNet-18 CNN model, trained on the ImageNet

database with parameters locked and further trained upon the NLST cohort as previously

described[10]. The ResNet model, Sybil, was run with default parameters on the same subset of

the NLST cohort comprised of 11,980 LDCT studies from 2,328 participants. The resulting

output from each LDCT image was a set of 6 values indicating the probability that lung cancer

was diagnosed within 1 to 6 years from the date of the CT study. In the UIH cohort, the ResNet

model was used on 4,092 LDCT studies from 1,104 participants. Each prediction score was

then compared with the ground truth values to determine the model's performance, broken

down into 6 performance evaluations by years 1 to 6.

<u>SVM + ResNet Hybrid Model Prediction</u>

For the hybrid computer vision model, SVM learning was used to train six unique models for

years 1-6 post imaging including the corresponding ResNet inferred risk for that given year.

Each ResNet + SVM model incorporates the ResNet risk inference of the current year and that

the training and testing samples are individual DICOMs associated with the clinical features of

each subject ID at baseline study entry. The training and test sets used the same allocation of

NLST participants used to train the previous ResNet model, and a 70:30 split of participants for

the UIH training cohort. To ensure equal comparison between the various models, training and

test sets had identical allocation of participants and corresponding DICOM files.

<u>ResNet ANN Model Prediction</u>

A simple fully connected artificial neural network (ANN) was constructed to incorporate race and

age along with a 1-year ResNet prediction score. There are thus 3 inputs: a numerical age, a

binary value (0 or 1) indicating if the participant is Black, and LDCT-based score generated by

the ResNet representing the probability of cancer diagnosis. Participants listed as "more than

one race" in the NLST cohort were evaluated as not Black. The ANN model has 6 outputs, each

output representing the probability of lung cancer diagnosis by year N (1 to 6). There are 2 fully

connected hidden layers. 100 independent ANNs were trained with Black race being weighted

to equalize the proportion in the UIH cohort. Using randomly initialized parameters, the top 10

performers on a validation set (a random 10% of the UIH cohort participants) were used to

create an ensemble to evaluate ResNet predictive performance on a held out test set (90% of

UIH participants).

<u>Evaluating Model Performance</u>

Model performance was evaluated on completely held out test sets within the NLST cohort as

well as the UIH cohort. Receiver operating characteristic (ROC) area-under-curve values

generated using the Scikit-Learn Python library. To evaluate other aspects of model

performance (i.e., specificity, PPV, NPV) a sensitivity cutoff as close to 0.8 as possible was

selected to mirror proposed sensitivities utilized in the International Lung Screening Trial for the

$PLCO_{m2012}$ model[20-22].

<u>Comparison of models and performance among populations</u>

To determine whether there was a significant difference in the ROC curve of a given model on a

similar population, DeLong's test[23] with a modified bootstrapping approach was utilized[24]. For

precision recall curve analysis on NLST White versus Black participants, 1000 times bootstrap

resampling was performed. Unpaired analysis on ROC curves was performed as previously

described by Hanley and McNeil[25].

RESULTS

NLST and UIH cohorts evaluated in this study and racial and ethnic breakdown initially

comprised of 53,452 participants in NLST and 11,654 participants in UIH (**Fig 1A-B, Table 1**).

We sought to develop a hybrid predictive model to combine the long-term predictive potential of

clinical features as well as near-term predictive potential of radiographic features from LDCT. To

develop a hybrid lung cancer prediction model, we used the NLST as a training data set

inclusive of CT scans and Chest X-Ray arms amounting to 48,628 total participants[2] for the

training of the support vector machine (SVM). A SVM model was chosen owing to its

interpretability of features and weights and allowed for multi-year risk prognostication from

baseline characteristics of participants at entry (**Figure 2A, eFigure 2**). The SVM was also

selected as it is effective at classifying two classes (i.e. those with no lung cancer diagnosis

versus those with lung cancer diagnosis) where ground-truth was measured by the time from

study entry to cancer incidence within the window of that year's specific model (e.g. SVM_1

predicts the probability of lung cancer within one year or less, SVM_2 within two years etc.). We

first focused on and initiated the SVM models with 65 features available in the NLST data and

utilized recursive feature elimination to optimize the model to 11 features (**eFigure 2, eTable 2**).

These 11 features overlapped with many previous features identified in the $PLCO_{m2012}$ 6-year

risk model but enabled the SVM to predict multi-year risk as opposed to single 6-year risk

(**eFigure 2**, **eTable 2**)[18]. We then further optimized the model for practical application by

eliminating features not captured in the UIH electronic health record during routine clinical care.

The excluded features included former vs current smoker, whether participants have a specific

family history of lung cancer, participants' education whether higher than bachelor's or not, and

the maximum number of years exposed to one of the following at work: asbestos, chemical,

sand blasting, coal, foundry. We found that the SVM model could be reduced to a pragmatic 7

clinical feature set while still retaining predictive performance in the NLST cohort (**Fig. 2B,**

eTable 3). Performance of the 7-feature multiyear SVM model was first evaluated in a held-out

test set from the NLST cohort with ROC-AUC values of 0.64-0.67 similar to the 6-year lung

cancer risk when compared to the $PLCO_{m2012}$ model (**eFigure 3, eTable 4**). We then applied the

model to the UIH cohort and found similar performance with ROC AUC 0.60-0.65 across years

and comparable Year 6 predictive performance when compared to the $PLCO_{m2012}$ and 11

feature SVM (**Figure 2B, eTable 4**).

Following initial model optimization of clinical risk features, we then incorporated an image-

based lung risk predictor of the ResNet-18 CNN image classifier with additional training on

LDCT images from NLST, Sybil[10], which infers lung cancer risk probabilities at multiple years of

follow up. This multimodal hybrid computer vision model was trained with the previously

identified 7 clinical features in the SVM but with inclusion of ResNet model risk inference from

65,161 LDCT study DICOM files in the NLST training set (**Figure 2C**). We then benchmarked

the hybrid computer vision model on the NLST test set compared to SVM models trained with

clinical risk features alone which resulted in a substantial and significant improvement of

predictive potential across all years (**Figure 2D**; ROC-AUC range 0.78-0.91, **eTable 5**). At a

sensitivity of 80% (corresponding to a $PLCO_{m2012}$ 6-year risk of 1.6%)[18] we found improvement

in specificity when compared to the $PLCO_{m2012}$ risk predictive model ((0.614 versus 0.411,

eTable 4)[18].

We then evaluated the hybrid computer vision model in the diverse UIH cohort and observed a

substantial decrease in model performance (**Figure 2D**; ROC AUC 0.68-0.80). Since we did not

observe a decrease between NLST and UIH cohorts in the 7 clinical feature SVM (**Figure 2B**),

we investigated the ResNet component of the Hybrid model to improve performance. To ensure

ResNet model inference was reproducible in our hands, we reanalyzed individual CT scans

from the NLST test set and confirmed findings as previously reported[10] (**eFigure 4, eTable 6**).

We then evaluated baseline LDCT scans using the ResNet model alone on the UIH cohort and

identified significantly reduced performance in the UIH cohort across all years with Year 1 ROC-

AUC values of 0.8 in UIH versus 0.92 in NLST, for example (**Table 2**, **eFigure 5**). We then

asked whether model performance deterioration[26] was due to a technical difference of the LDCT

scans (e.g. modern CT scanners and image reconstruction in UIH versus NLST) or due to the

demographic differences such as race. Evaluating performance of the ResNet model on White

participants in the UIH showed no significant differences in performance (**Table 2**) between the

NLST and the UIH cohorts. However, when assessed in Black participants, there was marked

and significant deterioration in model performance with Y1-Y6 ROC AUC values 0.65-0.75 as

compared to White participants in the UIH cohort (**Table 2**). Notably, ROC-AUC values in the

NLST cohort were not markedly different between White and Black subjects (**Table 2**) though a

low number of positive cases (e.g. 1 positive case at Year 1 in Black NLST subjects) led us to

examine Precision-Recall AUC (**Table 2**) which demonstrated a significant decrease in

performance in Black versus White subjects in NLST (**Table 2**). We also evaluated other

potential areas of model deterioration including ethnicity, sex, and BMI and found differences in

BMI where model performance had deterioration in obese individuals (BMI ≥ 30, **eTable 7**). In

the NLST cohort Y1 ROC AUC was 0.94 in BMI < 30 versus 0.88 in BMI ≥ 30 subjects (**eTable

7**). In the UIH cohort, we observed more pronounced model deterioration where Y1 ROC AUC

was 0.90 BMI < 30 versus 0.67 in BMI ≥ 30 subjects (**eTable 8**).

We then inquired whether ResNet model racial disparity could be mitigated by re-weighting the

NLST cohort to increase the proportion of Black participants to that of the UIH cohort, as well as

including an additional layer that incorporated race as an input. After training and testing an

ensemble of Artificial Neural Networks on the NLST training set with (**eTable 9**), we evaluated

the model in the UIH cohort and observed that ROC AUC values modestly increased in Black

subjects by 0.01 to 0.02 across Years 1-6 as compared to the ResNet model alone (**eTable 10,

Table 2**). However, in White subjects, there was a substantial decrease in performance in Y2-6

ROC-AUC values by 0.10 (**eTable 10**) as compared to the ResNet model alone (**Table 2**)

potentially reflecting a domain shift or interdependencies of other clinical factors with race. In

light of this domain shift and racial imbalance in the NLST cohort, we finally asked whether

retraining the hybrid-computer vision model using the UIH cohort could at least improve

performance in Black participants. Using a 70:30 training:test split, we observed an

improvement in model ROC-AUC ranging from 0.05-0.10 across years in all subjects and 0.1-

0.18 in Black subjects with significance in a subset of years (**Table 3**).

DISCUSSION

Lung cancer disparities are extensively characterized in Black populations with respect to

incidence, clinical management, screening, and survival. While LDCT screening has proven

effective in reducing mortality through early detection and improved survival[2,18], existing

guidelines have been shown to perpetuate inequities. The USPSTF LDCT criteria[18], primarily

based on the nearly 95% White NLST study population[2] has been shown to contribute to

disparities where Black screening eligible patients carry twice the risk of lung cancer as

compared to White populations[4,5]. Alternative strategies have been proposed including utilizing

clinical risk models to determine screening eligibility thereby mitigating disparities of risk[5,7].

While these strategies demonstrate increased sensitivity as compared to USPSTF criteria, they

have several limitations including patient selection only at long-term risk levels (> 1-1.5% lung

cancer risk), lack of risk adjustment from LDCT findings, limited PPV and NPV values, and

potential disparities in predictive performance (**eFigure 3**).

The hybrid computer vision model demonstrated the ability to individualize lung cancer risk in

NLST and UIH cohorts, though with higher performance among populations identifying as

White as compared to Black, potentially reflecting bias from an NLST training set comprised of

>95% White. Bias in AI models is an increasing concern, particularly among institutions serving

diverse patient populations and may further exacerbate health disparities[27]. However, many

initiatives are aiming to reduce bias in AI development including AIM-AHEAD[28] and specifically

in lung cancer screening, the National Cancer Institute's CANDID-4AI[23]. Because of the existing

disparities in lung cancer including the higher risk of lung cancer observed among Black

patients who smoke, implementation of AI models will require representative data in training

sets and inclusion of Black populations and other minorities in validation cohorts and

prospective studies. Furthermore, the domain shift we observed may suggest that lung

parenchymal features in White LDCT images possess different features and latent

representations than in Black individuals. However, our findings suggest that these may be

overcome with retraining with more representative data (**Table 3**). In addition, we observed

model deterioration in individuals with a BMI ≥ 30. While the underlying mechanism for this

deterioration in both the NLST and UIH cohorts was outside of the scope of this study, we

speculate that latent features within lung parenchyma may be inadequately visualized due to a

biological obesity paradox that confounds our hazard risk models[29,30]. Alternatively, chest wall

thickness from subcutaneous adipose tissue may interfere with ray penetration, or cause

compression of lung parenchyma due to obesity hypoventilation. Further research into this

phenomenon with appropriate radiology clinical domain expertise will improve generalizability

through addressing the root cause(s) at image acquisition, data processing, model

development, or inference[31,32].

This study has several limitations, chiefly those of the retrospective nature of the UIH cohort

which is subject to bias and data missingness. We are aiming to address these limitations with a

prospective study on new LDCT participants across multiple sites. The hybrid computer vision

model also utilizes a CNN architecture trained on the NLST cohort which has limited

representation of Black and other minoritized populations. Current efforts such as the CANDID-

4AI initiative[33] to develop more inclusive training sets would enable new models to overcome

the domain shifts we observed in the ResNet model[10] where performance in White subjects

decreased when the model was optimized for Black subjects. Having inclusive and

representative training sets with race labeling will allow ResNet and newer foundation models to

have greater generalizability and understand underlying features of lung cancer racial

disparities. In addition to more diverse training sets, domain adaptation and adversarial learning

to debias the NLST cohort are approaches we did not attempt but could also be

investigated[31,32,34]. Finally, the results of the retraining of the hybrid computer vision model on

the UIH population may represent overfitting to either technical or geographic factors in UIH

participants. To truly evaluate model performance and generalizability, a similarly diverse but a

geographically distinct cohort of LDCT subjects would be required.

Overall, we demonstrate that an integrated approach combining imaging and clinical features

can predict lung cancer risk at an individual level, and that model deterioration in Black

populations can potentially be overcome by retraining on more inclusive and representative

cohorts. Further validation of this approach and similar AI tools can assist clinicians in managing

risk reduction and preventive measures by estimating future lung cancer risk and identifying

high risk individuals. Lastly, accurate and equitable lung cancer risk assessments can enable

personalized initiation of LDCT screening which in turn may mitigate racial disparities in lung

cancer screening and survival.

ACKNOWLEDGEMENTS

We wish to thank the UIC Center for Clinical Translational Sciences for technical support, the UI Cancer Center Data Integrated Shared Resource (DISR) for their provision of population-level data and data visualization/mapping services., J.R., M.M.P, and F.D.W. for helpful discussions on the manuscript. A.J.Z. was supported by an AI.Health4all postdoctoral fellowship, M.B. was supported by a Winn-CIPP fellowship, A.A.S. received support as a National Cancer Institute, Center for Cancer Health Equity Early Investigator Advancement Program Scholar. A.J.Z., N.P., and A.A.S. conducted the data analysis presented in this manuscript. A.A.S. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis.

CONFLICTS OF INTEREST

A.A.S. and A.J.Z. have filed an invention disclosure related to this work. A.A.S. was recently employed by Tempus AI., Inc. and holds an equity interest. A.A.K. and V.K.G. have equity interests in Tempus AI.

DATA SHARING STATEMENT

All data and code used to generate figures and tables in this manuscript will be made available in a Zenodo repository upon the publication of this manuscript. Sharing of individual level deidentified data is subject to review and approval of the University of Illinois Chicago Institutional Review Board and will be distributed following the University of Illinois Chicago INDIGO repository standard practices under a Material Transfer Agreement.

 FIGURE LEGENDS

Figure 1 – Racial and ethnic distributions in the NLST and UIH cohorts **A)** Composition of races

and ethnicities in the National Lung Screening Trial (NLST) and UIH cohorts.

B) Geographic distribution of the UIH cohort with participants counted within zip codes.

Figure 2 – Training and testing schematics and performance of the clinical and hybrid computer

vision models in the NLST and UIH cohorts. **A)** Support Vector Machine (SVM) model schema

to predict lung cancer risk using NLST clinical and demographic data. **B)** 7-feature SVM

performance assessed by ROC curves in the NLST (left) and UIH cohorts (right). **C)** Hybrid

computer vision model (SVM + ResNet18) schema combining LDCT scans with clinical and

demographic data to predict lung cancer risk. **D)** Hybrid computer vision model performance

assessed by ROC curves in the NLST (left) and UIH cohorts (right).

TABLES

Table 1 – Population characteristics of the NLST and UIH cohorts

Characteristic	NLST	UIH
Race		
White	48,549	3,099
Black	2,376	6,447
Asian	1,095	210
American Indian or Alaska Native	190	68
Native Hawaiian or Other Pacific Islander	193	47
Other/No Information	1,049	1,783
Ethnicity		
Not Hispanic	52,118	9,514
Hispanic	935	1,170
No Information	399	970
Lung cancer incidence	3.2%	8.1%

Table 2 – ResNet performance comparison across races in the NLST and UIH cohorts

Year	ROC-AUC PR-AUC n negative n positive						P value ROC-AUC (Hanley-McNeil)						P value PR-AUC (bootstrap)
	NLST	UIH	NLST White	NLST Black	UIH White	UIH Black	NLST vs UIH	NLST White vs UIH White	NLST Black vs UIH Black	NLST White vs UIH Black	NLST White vs NLST Black	UIH White vs UIH Black	NLST White vs NLST Black
Y1	0.919 0.333 11832 144	0.796 0.268 3973 119	0.918 0.342 11234 139	0.991 0.125 290 1	0.97 0.465 932 28	0.737 0.224 2786 91	2.8×10^{-5}	6.1×10^{-2}	5.3×10^{-4}	1.3×10^{-7}	2.9×10^{-1}	7.4×10^{-10}	6.0×10^{-3}
Y2	0.856 0.261 11702 243	0.731 0.269 2686 166	0.853 0.269 11111 234	0.93 0.249 284 4	0.846 0.478 644 62	0.687 0.220 1881 124	5.0×10^{-6}	8.7×10^{-1}	8.8×10^{-3}	1.5×10^{-4}	3.9×10^{-1}	4.6×10^{-5}	3.8×10^{-2}
Y3	0.804 0.239 11479 342	0.713 0.329 1954 198	0.803 0.243 10907 327	0.851 0.189 272 6	0.789 0.436 470 62	0.677 0.306 1370 136	4.0×10^{-4}	7.1×10^{-1}	8.9×10^{-2}	2.9×10^{-5}	6.3×10^{-1}	1.1×10^{-2}	1×10^{-3}
Y4	0.775 0.224 11256 444	0.701 0.340 1720 204	0.774 0.225 10707 424	0.719 0.156 261 8	0.791 0.459 426 68	0.657 0.310 1187 142	3.1×10^{-3}	6.9×10^{-1}	5.6×10^{-1}	6.7×10^{-5}	6.0×10^{-1}	2.3×10^{-3}	7×10^{-3}
Y5	0.762 0.224 10972 547	0.707 0.417 1287 217	0.76 0.222 10439 522	0.716 0.19 258 8	0.806 0.550 327 68	0.657 0.387 884 149	1.1×10^{-2}	2.0×10^{-1}	5.8×10^{-1}	3.2×10^{-4}	6.7×10^{-1}	4.0×10^{-4}	2×10^{-3}
Y6	0.752 0.233 10303 595	0.695 0.466 866 230	0.752 0.232 9805 567	0.7 0.189 233 8	0.782 0.596 229 70	0.653 0.445 567 160	1.7×10^{-2}	4.1×10^{-1}	6.9×10^{-1}	5.0×10^{-4}	5.7×10^{-1}	2.8×10^{-3}	0.00

456 **Table 3 –** Predictive performance metrics of the hybrid computer vision model after
457 retraining on 70% of the UIH cohort and testing on a 30% held out set.
458

	Year	n negative n positive	ResNet ROC-AUC	Retrained hybrid computer vision ROC-AUC	*P* Bootstrapped Delong's Test
All subjects	1	1163 34	0.68	0.78	2.9×10^{-4}
	2	754 49	0.66	0.76	6.7×10^{-3}
	3	530 52	0.66	0.75	1.1×10^{-2}
	4	475 55	0.65	0.70	9.1×10^{-2}
	5	341 58	0.66	0.73	2.3×10^{-2}
	6	239 60	0.65	0.79	5.1×10^{-7}
Black subjects	1	751 28	0.59	0.67	1.5×10^{-3}
	2	475 43	0.58	0.68	1.4×10^{-2}
	3	337 46	0.59	0.74	3.2×10^{-4}
	4	289 49	0.58	0.70	4.1×10^{-3}
	5	173 52	0.59	0.70	2.7×10^{-3}
	6	123 54	0.56	0.74	3.29×10^{-8}
non-Black subjects	1	412 6	1	1	NA
	2	279 6	1	1	NA
	3	203 6	1	1	NA
	4	186 6	1	1	NA
	5	148 6	1	1	NA
	6	116 6	1	1	NA

REFERENCES

1. Soneji S, Tanner NT, Silvestri GA, Lathan CS, Black W. Racial and Ethnic Disparities in Early-Stage Lung Cancer Survival. *Chest*. Sep 2017;152(3):587-597. doi:10.1016/j.chest.2017.03.059

2. National Lung Screening Trial Research T, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. *N Engl J Med*. Aug 4 2011;365(5):395-409. doi:10.1056/NEJMoa1102873

3. Bandi P, Star J, Ashad-Bishop K, Kratzer T, Smith R, Jemal A. Lung Cancer Screening in the US, 2022. *JAMA Intern Med*. Jun 10 2024;doi:10.1001/jamainternmed.2024.1655

4. Pinsky PF, Lau YK, Doubeni CA. Potential Disparities by Sex and Race or Ethnicity in Lung Cancer Screening Eligibility Rates. *Chest*. Jul 2021;160(1):341-350. doi:10.1016/j.chest.2021.01.070

5. Aredo JV, Choi E, Ding VY, et al. Racial and Ethnic Disparities in Lung Cancer Screening by the 2021 USPSTF Guidelines Versus Risk-Based Criteria: The Multiethnic Cohort Study. *JNCI Cancer Spectr*. May 2 2022;6(3)doi:10.1093/jncics/pkac033

6. Choi E, Ding VY, Luo SJ, et al. Risk Model-Based Lung Cancer Screening and Racial and Ethnic Disparities in the US. *JAMA Oncol*. Oct 26 2023;doi:10.1001/jamaoncol.2023.4447

7. Pasquinelli MM, Tammemagi MC, Kovitz KL, et al. Risk Prediction Model Versus United States Preventive Services Task Force Lung Cancer Screening Eligibility Criteria: Reducing Race Disparities. *J Thorac Oncol*. Nov 2020;15(11):1738-1747. doi:10.1016/j.jtho.2020.08.006

8. Field JK, Vulkan D, Davies MPA, Duffy SW, Gabe R. Liverpool Lung Project lung cancer risk stratification model: calibration and prospective validation. *Thorax*. Feb 2021;76(2):161-168. doi:10.1136/thoraxjnl-2020-215158

9. Katki HA, Kovalchik SA, Berg CD, Cheung LC, Chaturvedi AK. Development and Validation of Risk Models to Select Ever-Smokers for CT Lung Cancer Screening. *JAMA*. Jun 7 2016;315(21):2300-11. doi:10.1001/jama.2016.6255

10. Mikhael PG, Wohlwend J, Yala A, et al. Sybil: A Validated Deep Learning Model to Predict Future Lung Cancer Risk From a Single Low-Dose Chest Computed Tomography. *J Clin Oncol*. Apr 20 2023;41(12):2191-2200. doi:10.1200/JCO.22.01345

11. Heuvelmans MA, van Ooijen PMA, Ather S, et al. Lung cancer prediction by Deep Learning to identify benign lung nodules. *Lung cancer*. Apr 2021;154:1-4. doi:10.1016/j.lungcan.2021.01.027

12. Ardila D, Kiraly AP, Bharadwaj S, et al. End-to-end lung cancer screening with three-dimensional deep learning on low-dose chest computed tomography. *Nature medicine*. Jun 2019;25(6):954-961. doi:10.1038/s41591-019-0447-x

13. Liao F, Liang M, Li Z, Hu X, Song S. Evaluate the Malignancy of Pulmonary Nodules Using the 3-D Deep Leaky Noisy-OR Network. *IEEE transactions on neural networks and learning systems*. Nov 2019;30(11):3484-3495. doi:10.1109/TNNLS.2019.2892409

14. Centers for Disease C, Prevention. Racial/Ethnic disparities and geographic differences in lung cancer incidence --- 38 States and the District of Columbia, 1998-2006. *MMWR Morb Mortal Wkly Rep*. Nov 12 2010;59(44):1434-8.

15. Byrne CA, Gomez SL, Kim S, Oddo VM, Koh TJ, Fantuzzi G. Disparities in inflammation between non-Hispanic black and white individuals with lung cancer in the Greater Chicago Metropolitan area. *Front Immunol*. 2022;13:1008674. doi:10.3389/fimmu.2022.1008674

16. Watson KS, Hulbert A, Henderson V, et al. Lung Cancer Screening and Epigenetics in African Americans: The Role of the Socioecological Framework. *Front Oncol*. 2019;9:87. doi:10.3389/fonc.2019.00087

17. Kim SJ, Kery C, An J, Rineer J, Bobashev G, Matthews AK. Racial/Ethnic disparities in exposure to neighborhood violence and lung cancer risk in Chicago. *Soc Sci Med*. Jan 2024;340:116448. doi:10.1016/j.socscimed.2023.116448

18.   Tammemagi MC, Katki HA, Hocking WG, et al. Selection criteria for lung-cancer
screening. *N Engl J Med*. Feb 21 2013;368(8):728-36. doi:10.1056/NEJMoa1211776
19.   Pedregosa F, Varoquaux G, Gramfort A, et al. Scikit-learn: Machine learning in Python.
the Journal of machine Learning research. 2011;12:2825-2830.
20.   Weber M, Yap S, Goldsbury D, et al. Identifying high risk individuals for targeted lung
cancer screening: Independent validation of the PLCO(m2012) risk prediction tool. *Int J Cancer*.
Jul 15 2017;141(2):242-253. doi:10.1002/ijc.30673
21.   Tammemagi MC, Ruparel M, Tremblay A, et al. USPSTF2013 versus PLCOm2012 lung
cancer screening eligibility criteria (International Lung Screening Trial): interim analysis of a
prospective cohort study. *Lancet Oncol*. Jan 2022;23(1):138-148. doi:10.1016/S1470-
2045(21)00590-8
22.   Force USPST, Krist AH, Davidson KW, et al. Screening for Lung Cancer: US Preventive
Services Task Force Recommendation Statement. *JAMA*. Mar 9 2021;325(10):962-970.
doi:10.1001/jama.2021.1117
23.   DeLong ER, DeLong DM, Clarke-Pearson DL. Comparing the areas under two or more
correlated receiver operating characteristic curves: a nonparametric approach. *Biometrics*. Sep
1988;44(3):837-45.
24.   Demler OV, Pencina MJ, D'Agostino RB, Sr. Misuse of DeLong test to compare AUCs
for nested models. *Stat Med*. Oct 15 2012;31(23):2577-87. doi:10.1002/sim.5328
25.   Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating
characteristic (ROC) curve. *Radiology*. Apr 1982;143(1):29-36.
doi:10.1148/radiology.143.1.7063747
26.   Zhang A, Xing L, Zou J, Wu JC. Shifting machine learning for healthcare from
development to deployment and from models to data. *Nat Biomed Eng*. Dec 2022;6(12):1330-
1345. doi:10.1038/s41551-022-00898-y
27.   Crowe B, Rodriguez JA. Identifying and Addressing Bias in Artificial Intelligence. *JAMA
Netw Open*. Aug 1 2024;7(8):e2425955. doi:10.1001/jamanetworkopen.2024.25955
28.   Hendricks-Sturrup R, Simmons M, Anders S, et al. Developing Ethics and Equity
Principles, Terms, and Engagement Tools to Advance Health Equity and Researcher Diversity
in AI and Machine Learning: Modified Delphi Approach. *JMIR AI*. Dec 6 2023;2:e52888.
doi:10.2196/52888
29.   Cespedes Feliciano EM, Kroenke CH, Caan BJ. The Plausibility of the Obesity Paradox
in Cancer-Response-Reply to Point. *Cancer Res*. Apr 15 2018;78(8):1904-1905.
doi:10.1158/0008-5472.CAN-17-3590
30.   Park Y, Peterson LL, Colditz GA. The Plausibility of Obesity Paradox in Cancer-Point.
Cancer Res. Apr 15 2018;78(8):1898-1903. doi:10.1158/0008-5472.CAN-17-3043
31.   Kim W. Seeing the Unseen: Advancing Generative AI Research in Radiology. *Radiology*.
May 2024;311(2):e240935. doi:10.1148/radiol.240935
32.   Banerjee I, Bhattacharjee K, Burns JL, et al. "Shortcuts" Causing Bias in Radiology
Artificial Intelligence: Causes, Evaluation, and Mitigation. *J Am Coll Radiol*. Sep 2023;20(9):842-
851. doi:10.1016/j.jacr.2023.06.025
33.   Institute NC. Leveraging Artificial Intelligence to Improve Accuracy of Lung Cancer
Screening was originally published by the National Cancer Institute. 2024.
https://prevention.cancer.gov/news-and-events/blog/leveraging-artificial-intelligence-improve-
accuracy-lung-cancer-screening
34.   Yang J, Soltan AAS, Eyre DW, Yang Y, Clifton DA. An adversarial training framework for
mitigating algorithmic biases in clinical machine learning. *NPJ Digit Med*. Mar 29 2023;6(1):55.
doi:10.1038/s41746-023-00805-y
579

Figure 1

Figure 2